785046-14-2

Upstream product

• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 313339-35-4 4,6-dichloro-2-(methylsulfanyl)pyrimidine-5-carboxylic acid 
• 606971-58-8 N-[3,5-bis(trifluoromethyl)benzyl]-N-[3-(t-butoxycarbonylamino)propyl]-4,6-dichloro-2-(methylthio)pyrimidine-5-carboxylic acid amide 

Downstream Products

• 606971-74-8 6-[3,5-bis(trifluoromethyl)benzyl]-4-(2-methylphenyl)-2-methylthio-5,6,7,8,9,10-hexahydropyrimido[4,5-b][1,5]diazocin-5-one 
• 606971-80-6 6-[3,5-bis(trifluoromethyl)benzyl]-4-(2-methylphenyl)-2-methylsulfonyl-5,6,7,8,9,10-hexahydropyrimido[4,5-b][1,5]diazocin-5-one 
• 606971-30-6 2-(4-acetylpiperazine-1-yl)-6-[3,5-bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-5-oxopyrimido[4,5-b][1,5]diazocine 
• 606971-64-6 6-[3,5-bis(trifluoromethyl)benzyl]-4-chloro-2-methylthio-5,6,7,8,9,10-hexahydropyrimido[4,5-b][1,5]diazocin-5-one 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists

A series of novel bicyclic pyrimidine derivatives was prepared as part of a search for NK1 antagonist aimed at the treatment of urinary incontinence. Among them, 3g, a pyrimido[4,5-b][1,5]oxazocine derivative, bearing a 4-acetylpiperazinyl grou